UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000055505
Receipt number R000063426
Scientific Title A study for commercialization of diabetes prevention by a personalized health support app corresponding to diversity of lifestyles
Date of disclosure of the study information 2024/10/01
Last modified on 2025/10/07 18:52:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study for commercialization of diabetes prevention by a personalized health support app corresponding to diversity of lifestyles

Acronym

A study for commercialization of diabetes prevention by a personalized health support app corresponding to diversity of lifestyles

Scientific Title

A study for commercialization of diabetes prevention by a personalized health support app corresponding to diversity of lifestyles

Scientific Title:Acronym

A study for commercialization of diabetes prevention by a personalized health support app corresponding to diversity of lifestyles

Region

Japan


Condition

Condition

person receiving health checkups

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We will distribute a smartphone application with health promotion functions with incentives to people who have undergone health checkups, and verify its usefulness in improving their lifestyles for diabetes prevention and its practical application.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase I


Assessment

Primary outcomes

Changes in physical findings (weight, abdominal circumference, BMI)

Key secondary outcomes

Changes in physical examination (blood pressure, body composition (Inbody) test), blood and urine tests (blood count, AST, ALT, GGT, ALP, LDH, T-bil, BUN, CRE, LDL cholesterol, HDL cholesterol, total cholesterol, serum triglycerides, blood sugar, HbA1c, uric acid, electrolytes, urine test )


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Device,equipment

Interventions/Control_1

Intervention to distribute a smartphone application (smartphone application, hereinafter referred to as application) researched and developed by the representative research institute, Delicious Health Corporation, to examinees of health checkups (specified health checkups, statutory health checkups, and physical examinations) at the joint research institute.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Persons receiving medical examinations at Asahi University Hospital, Kameoka Municipal Hospital, Shin-Oyama Municipal Hospital, and Takata Central Hospital
2) Persons who can obtain consent to participate in the research of their own free will from the individual via the application.
(iii) Age: 20 to 90 years old

Key exclusion criteria

1.Women who are pregnant or may become pregnant
2.BMI less than 22 kg/m2
3.Diabetics, kidney disease patients, and others who need to follow diet therapy under the guidance of a physician
4.People whose attending physician deems it inappropriate

Target sample size

2200


Research contact person

Name of lead principal investigator

1st name Tetsuya
Middle name
Last name Nojiri

Organization

Oishi Kenko Inc.

Division name

CEO

Zip code

103-0024

Address

3F Libra Building, 3-2 Nihonbashi Kobunacho, Chuo-ku, Tokyo

TEL

03-6661-0081

Email

tetsuya@oishi-kenko.com


Public contact

Name of contact person

1st name Kazuki
Middle name
Last name Hamada

Organization

Oishi Kenko Inc.

Division name

Development Department

Zip code

103-0024

Address

3F Libra Building, 3-2 Nihonbashi Kobunacho, Chuo-ku, Tokyo

TEL

03-6661-0081

Homepage URL

https://corp.oishi-kenko.com/

Email

manemone@oishi-kenko.com


Sponsor or person

Institute

Oishi Kenko Inc.

Institute

Department

Personal name

Tetsuya Nojiri


Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Oishi Kenko Inc.

Address

3F Libra Building, 3-2 Nihonbashi Kobunacho, Chuo-ku, Tokyo

Tel

03-6661-0081

Email

tetsuya@oishi-kenko.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

朝日大学病院(岐阜県)、亀岡市立病院(京都府)、地方独立行政法人 新小山市民病院(栃木県)、医療法人すこやか 高田中央病院(東京都)


Other administrative information

Date of disclosure of the study information

2024 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

138

Results

A total of 255 individuals were approached across four facilities, of whom 149 consented, and 138 ultimately started using the app. At 90 days, 63 participants (45.7%) continued app usage. In the continued-use group, body weight decreased by an average of 1.99 kg and waist circumference by 3.13 cm, both showing statistically significant reductions. Additionally, app usage frequency was significantly correlated with the amount of body weight change.

Results date posted

2025 Year 10 Month 07 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2024 Year 10 Month 01 Day

Date of IRB

2024 Year 11 Month 12 Day

Anticipated trial start date

2024 Year 10 Month 15 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry

2025 Year 03 Month 31 Day

Date trial data considered complete

2025 Year 04 Month 30 Day

Date analysis concluded

2025 Year 05 Month 31 Day


Other

Other related information



Management information

Registered date

2024 Year 09 Month 15 Day

Last modified on

2025 Year 10 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000063426